Logo

Correlation between serum levels of RANKL with osteoporosis in patients with beta thalassemia major

Author(s):
Fatemeh JafariFatemeh Jafari, Azita AzarkeivanAzita Azarkeivan, Davod BashashDavod Bashash, Ali Akbar Khadem MaboodiAli Akbar Khadem Maboodi, mohsen hamidpourmohsen hamidpourmohsen hamidpour ORCID,*

Koomesh:Vol. 21, issue 1; 150-154
Published online:Mar 05, 2019
Article type:Research Article
Received:Apr 02, 2018
Accepted:Sep 05, 2018
How to Cite:Fatemeh JafariAzita AzarkeivanDavod BashashAli Akbar Khadem Maboodimohsen hamidpourCorrelation between serum levels of RANKL with osteoporosis in patients with beta thalassemia major.koomesh.21(1):e153051.

Abstract

References

  • 1.
    Jalali H, Mahdavi MR, Roshan P, Kosaryan M, Karami M, Mahdavi M. Alpha thalassemia gene mutations in neonates from Mazandaran, Iran, 2012. Hematology 2014; 19: 192-195. (Persian).
  • 2.
    Moradi G, Ghaderi E. Chronic disease program in Iran: Thalassemia control program. Chronic Dis J 2013; 1: 98-106.
  • 3.
    Galehdari H, Salehi B, Bijan Keikhaei S, Zandian KM, Pedram M. Comprehensive spectrum of the -thalassemia mutations in Khuzestan, Southwest Iran. Hemoglobin 2010; 34: 461-468.
  • 4.
    Prabhu R, Prabhu V. Iron overload in beta thalassemia: a review. J Biosci Tech 2009; 1: 20-31.
  • 5.
    Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis2010; 5: 11-18.
  • 6.
    McLaren CE, Barton JC, Adams PC, Harris EL, Acton RT, Press N, et al. Hemochromatosis and IronOverload Screening (HEIRS) study design for an evaluation of 100,000 primary care-basedadults. Am J Med Sci 2003; 325: 53-62.
  • 7.
    Kattamis AC, Antoniadis M, Manoli I, Kitra V, Petropoulos D, Grafakos S. Endocrine problems in ex-thalassemic patients. Transfus Sci2000; 23: 251-252.
  • 8.
    Mohammadian S, Bazrafshan U, Sadeghi-Nejad A. Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab2003; 16: 957-964.
  • 9.
    Khashayar P, Aghaei Meybodi HR, Rezai Homami M, Heshmat R, Larijani B. The prevalence of osteoporosis in an Iranian population. J Clin Densitometr 2010; 13: 112-119. (Persian).
  • 10.
    Salehi Abari I, Khazaeli S, Najafizadeh R, Malekpour M. High prevalence of low bone density in young Iranian healthy individuals.Clin Rheumatol2009; 28: 173-177.
  • 11.
    De Sanctis V, Soliman AT, Elsedfy H, Yassin M, Canatan D, Kilinc Y, et al. Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 2013; 11: 167-180.
  • 12.
    Rossi F, Perrotta S, Bellini G, Luongo L, Tortora C, Siniscalco D, et al. Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica 2014; 99: 1876-1884.
  • 13.
    Voskaridou E, Terpos E.New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004; 127: 127-139.
  • 14.
    Skordis N, Efstathiou E, Kyriakou A, Toumba M. Hormonal dysregulation and bones in thalassaemia--an overview.Pediatr Endocrinol Rev 2008; 6: 107-115.
  • 15.
    Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, et al. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992; 14: 48-56.
  • 16.
    Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an overview. J Osteoporos 2010; 2010: 1-8.
  • 17.
    Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-553.
  • 18.
    Saki N, Abroun S, Salari F, Fakher R, Shahjahani M, Mohammadi-Asl J. Molecular aspects of bone resorption in -thalassemia major. Cell J (Yakhteh) 2015; 17: 193-199. (Persian).
  • 19.
    Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998; 103: 911-915.
  • 20.
    Ilich JZ, Kerstetter JE. Kerstetter, Nutrition in bone health revisited: a story beyond calcium. J Am Coll Nutr 2000; 19: 715-737.
  • 21.
    WHO study group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.WHO technical report series 843, 1994.Geneva. http://www.who.int/iris/handle/10665/39142.
  • 22.
    Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004; 19: 722-727.
  • 23.
    Morabito N, Catalano A, Gaudio A, Morini E, Bruno LM, Basile G, et al. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis. J Bone Miner Metab 2016; 34: 540-546.
  • 24.
    Salah H, Atfy M, Fathy A, Atfy M, Mansor H, Saeed J. The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in egyptianpatients. Immunol Invest 2010; 39: 820-832.
  • 25.
    Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, et al. Circulating osteoprotegerin and receptor activator of NF-B ligand system in patients with -thalassemia major. J Bone Miner Metab 2007; 25(1): 60-67.
  • 26.
    Hamidi Z, Sedaghat M, Mortaz Hejri S, Larijani B. Defining cut-off values for the diagnosis of osteoporosis in postmenopausal women by quantitative ultrasonography of the phalanx. Gynecol Endocrinol2008; 24: 546-554.
  • 27.
    Wong P, Fuller PJ, Gillespie MT, Milat F. Bone disease in thalassemia: amolecular and clinical overview. Endocr Rev 2016; 37: 320-346.
  • 28.
    Kwiatkowski JL. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med 2011;2: 135-149.
  • 29.
    Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005; 202: 199-211.
  • 30.
    Khosla S. Minireview: The opg/rankl/rank system. Endocrinology 2001; 142: 5050-5055.
  • 31.
    Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKLRANK signaling in osteoclastogenesis and bone disease.Trends Mol Med2006; 12: 17-25.
  • 32.
    Jeney V. Clinical impact and cellular mechanisms of iron overload-associated bone loss.Front Pharmacol2017; 8: 1-11.
comments

Leave a comment here

Share on
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles